During this past week, South Korea and Kazakhstan signed commercial agreements worth US$18.95 billion. Kazakhstan is a country of 20 million people with its core industries being oil and gas, and among the highest producers of iron and silver in the world. Uzbekistan is a country of 39 million people, and they are the largest electricity producer in Central Asia.

Qazaqstan Investment Corporation (QIC) is Kazakhstan’s national fund of funds and are anchor investors along with IT Park Ventures, the venture capital arm of the country’s state technology park. The new venture capital fund will back Central Asian startups at the Series A and later, which are businesses with a proven model that are ready to scale beyond the region. The fund is sector-agnostic but focuses on AI-native companies, where artificial intelligence is core to the product and business model.

“Higgsfield becoming Kazakhstan’s first unicorn was a turning point. It showed that a world-class AI company can be built in Central Asia. And it won’t be the last with more than half of the region’s population is under 30, growing up digital and our governments actively investing in AI. Yet the region is still largely overlooked by international investors, and that’s the opportunity this fund is built for,” explained Aslan Sultanov, Co-founder and General Partner at SparkLabs Mirae Silk Road.

Former Coinbase CTO and Partner at Andreessen Horowitz, Balaji Srinivasan, reopened his Network School in Kazakhstan last month. Telegram launched an AI lab and opened their first regional office in Kazakhstan this past year.

Beyond capital, portfolio companies will gain access to the SparkLabs and Mirae Asset’s global networks, along with hands-on support in expanding into South Korea, the United States and the MENA region.

About the Partners

SparkLabs Group is a network of startup accelerators and venture capital funds that has invested in over 600 startups across 6 continents since December 2013. These companies include OpenAI, SpaceX, Vectara, Kneron, Anthropic, Nex Team, Kraken, GenG, Lyft, MetAI, and others.

Mirae Asset Venture Investment is the venture capital arm of Mirae Asset Financial Group, one of Asia’s largest independent financial groups with over US$845 billion in assets under management. The company operates worldwide across 18 markets, and manages a fully diversified global investment platform encompassing ETFs, alternative investments, and traditional strategies.

Qazaqstan Investment Corporation (QIC) is Kazakhstan’s national fund of funds and part of Baiterek National Managing Holding. QIC invests in private equity and venture capital funds alongside international and private partners, with the goal of attracting long-term capital into Kazakhstan and developing the country’s investment ecosystem. QIC participates in 19 funds with a combined capitalization of $2.8 billion.

IT Park Ventures is the venture capital arm of IT Park Uzbekistan, the country’s state technology park and the main platform supporting Uzbekistan’s IT industry and tech exports. IT Park Ventures invests in startups from Uzbekistan and Central Asia and co-invests with international funds, connecting regional founders with global capital and markets.

SOURCE SparkLabs Group

SHANGHAI, Sept. 20, 2026 — The inaugural S2S China Symposium has announced the finalists of its 2026 program. Co-hosted by RA Capital Management and Qiming Venture Partners, S2S China is the China chapter of Science2Startup, an invitation-only symposium connecting top academic researchers with leading biotech investors. Ten standout biotech startup teams were selected from a highly competitive pool of applicants. They will refine their projects through a dedicated mentorship program and pitch to top global venture investors at an on-site event held at Westlake University on October 15.

S2S was founded in 2018 by F-Prime, SV Health and Atlas Venture; RA Capital Management, Osage University Partners and 5AM Ventures have since joined the program. It connects therapeutics researchers at top academic and research institutions with leading biotech investors, pharma scouts, and industry executives. The program provides selected teams with mentorship and a platform to present novel, proprietary science with a path toward company formation and clinical development.

This year’s S2S China drew enthusiastic participation from researchers and early-stage founders across China’s therapeutics research ecosystem. Following multiple rounds of rigorous review by an advisory group of experienced biopharma investors, the competition narrowed a large field of submissions to roughly 20 semifinalist teams, and ultimately selected ten standout teams to advance to the finals and present at the October 15 on-site pitch event.

To help the participating teams connect effectively with the capital markets and strengthen their overall project framework, the finalists will take part in a dedicated mentorship program ahead of the event. Over the coming weeks, the teams will work alongside the S2S China Symposium advisory group, made up of experienced biotech investors and industry operators, to refine their scientific plans, sharpen their commercial narratives and polish their pitch content, raising the maturity of each project and laying a solid foundation for the on-site presentations and funding conversations that follow.

This year’s S2S China Symposium is supported by prominent figures from academia and the global life sciences investment community, including Shi Yigong, President of Westlake University; Kan Chen, Partner and Healthcare Co-Lead at Qiming Venture Partners; and Josh Resnick, Partner at RA Capital Management. Their deep involvement underscores the symposium’s value as a bridge between China’s academic research ecosystem and the global biotech venture community, while continuing the model established by the original Science2Startup symposium.

The event brings together a number of globally recognized institutions and biopharma leaders, forming a powerful supporting ecosystem. This year’s S2S China Symposium would not be possible without the strong support of leading companies across the industry, including our Platinum Sponsors Goodwin, Eli Lilly and Biocytogen, as well as Johnson & Johnson (Gold Sponsor) and Sanofi (Silver sponsor). The partnership of our sponsors reflects a shared commitment to advancing early-stage, academically-derived therapeutics innovation from China onto the global stage.

Platinum Sponsors

Goodwin is a global law firm at the intersection of capital and innovation, representing innovators and investors across healthcare, investment funds & capital, life sciences, private equity, real estate, and technology.  With more than 2,800 professionals worldwide, Goodwin combines industry knowledge, legal excellence, and business advisory expertise to help clients navigate complex challenges and seize opportunities in a rapidly changing, technology-driven economy.  We represent clients throughout the full corporate lifecycle, including company formation, financings, capital markets transactions, licensing and collaborations, M&A, regulatory matters, and exit strategies.  Learn more: https://www.goodwinlaw.com/en

Eli Lilly and Company is a global pharmaceutical leader headquartered in Indianapolis, Indiana, dedicated to discovering and delivering medicines that make life better for people around the world. With a deep commitment to scientific innovation, Lilly has been an active partner to the region’s biotech ecosystem, supporting early discovery through late-stage development across a range of therapeutic areas.

Biocytogen is a global biotechnology company discovering and developing next-generation antibody therapeutics across multiple modalities. The company has built a broad portfolio of novel drug candidates spanning monoclonal and bispecific antibodies, ADCs, VHH-based therapeutics, and other antibody-based modalities, with multiple programs advancing into clinical development both internally and through global licensing partnerships. Powered by its proprietary RenMice® platforms and large-scale antibody discovery engine, Biocytogen has generated more than one million fully human antibody sequences across over 1,000 therapeutic targets and established partnerships with more than 455 biopharmaceutical companies worldwide.

Gold Sponsor

Johnson & Johnson is a global healthcare leader, headquartered in New Brunswick, New Jersey, committed to solving the toughest health challenges and transforming lives through research, development, manufacture and distribution of medicines and medical technologies. The company’s Innovative Medicine business advances breakthrough science and develops transformational treatments in areas like oncology, immunology, neuroscience, and cardiopulmonary. In MedTech, the company is focused on developing and delivering cardiovascular, surgery, and vision solutions.

Silver Sponsor

Sanofi is a global biopharmaceutical company headquartered in Paris, France, dedicated to pursuing scientific breakthroughs that improve people’s lives. The company focuses on immunology, oncology, neurology, rare diseases, ophthalmology and vaccines, and maintains a significant R&D and commercial presence in China, where it has long invested in partnerships with local academic and biotech innovators to expand its global pipeline.

More information is available at s2schina.com/s2s/en.

About Qiming Venture Partners

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status.

Many of our portfolio companies are today’s most influential firms in their respective sectors, including  Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Hesai Technology, UBTech, WeRide, HyperStrong, Insta360, Unisound, Biren Technology, Z.ai, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech, Insilico Medicine, AusperBio, Yuanxin Technology, Medilink Therapeutics, LaNova Medicines, StepFun, among many others.

LONDON, Sept. 18, 2026 — Nscale Limited (“Nscale”) today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Nscale has applied to list its ordinary shares on the New York Stock Exchange under the ticker symbol “NSCL.”

Goldman Sachs & Co. LLC, J.P. Morgan and Morgan Stanley will act as lead bookrunners for the proposed offering. RBC Capital Markets, BofA Securities, Deutsche Bank Securities, Credit Agricole CIB, TD Securities, Mizuho, KeyBanc Capital Markets, Cantor, SMBC Nikko and Wolfe | Nomura Alliance will act as bookrunners for the proposed offering.  Citizens Capital Markets, Loop Capital Markets, Roth Capital Partners, ABN AMRO, Compass Point, DNB Carnegie, Rosenblatt, SEB and Tigress Financial Partners will act as co-managers for the proposed offering.

The proposed offering will be made available only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282 or by email: [email protected]; J.P. Morgan Securities LLC, Attention: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email: [email protected] and [email protected]; or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick St., 2^nd Floor, New York, New York 10014.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Nscale

Nscale Limited (Nscale) is a full-stack AI cloud platform. We bring together software, compute, and power in a vertically integrated offering – from a unified cloud platform for running AI training and inference, to the data centers and low-cost power that make it possible. Our mission is to build the engine of superintelligence and enhance access to the benefits of advanced AI for enterprises, governments, and the communities that depend on them.

SOURCE Nscale

DALLAS, Sept. 18, 2026 — Vestie is an investing platform designed for beginner investors, specifically women, who want to start investing but don’t know what to buy, when to start, or how to build a portfolio.

Vestie’s philosophy is simple: You don’t need to become a stock market expert to build wealth. Vestie is designed to help people start investing, automate the process, and stay invested for the long term. It’s your investing bestie — making investing feel more like getting help from a knowledgeable friend and less like walking into a Wall Street trading desk.

Founder and CEO Dana Bentz created Vestie after seeing how intimidating investing can feel to people who weren’t already immersed in finance. She built the product she wished existed when she first decided, “Okay, I know I should invest… Now what?” Most investment platforms were built around either active trading or traditional financial advisory experiences, and feature difficult-to-understand dashboards. Vestie is intentionally designed around simplicity, automation, and a beginner-friendly experience.

Users answer a short onboarding questionnaire regarding their investing goals, experience, and risk tolerance. They then receive a recommended diversified portfolio based on their unique answers, connect their bank account, fund their account, and can optionally set up recurring investments.

Vestie, Inc. is an investment adviser registered with the U.S. Securities and Exchange Commission*. Dana Bentz serves as the company’s CEO and as an investment adviser representative of Vestie, and says, “A lot of women know they should be investing. The problem isn’t convincing them that investing matters; it’s making that first step feel supported and simple enough to actually take.”

The company built a waitlist of roughly 500 people before public launch, demonstrating demand before the full product was available. Vestie is subscription-based rather than relying on users to constantly trade. Users can get started completely free, with access to advanced features for $14 per month or $139 per year. Vestie’s ambition is to become the financial platform women rely on when they decide they want to start investing and building wealth.

Vestie is available at https://vestie.com/, where users can create an account and begin investing.

*Registration with the SEC does not imply a certain level of skill or training.

Kelsey Bentz, [email protected]

SOURCE Vestie, Inc.

• ImpriMed combines ex vivo functional testing with multimodal AI to support personalized cancer treatment decisions and drug development
• The investment is part of ImpriMed’s $10 million Series A2 bridge round as the company advances U.S. commercialization and expands into Asia
• NAVER D2SF to strengthen its global healthcare founder community through its healthcare network and go-to-market expertise

SEOUL, South Korea, Sept. 18, 2026 — NAVER D2SF, NAVER’s inhouse corporate venture arm, has invested in ImpriMed, a Silicon Valley-based precision medicine company, joining ImpriMed’s $10 million Series A2 bridge round. ImpriMed develops AI-driven precision medicine solutions that combine ex vivo analysis of patient-derived live cancer cells with genomic, immunophenotypic, and clinical data to support personalized treatment decisions. NAVER D2SF’s investment reflects ImpriMed’s commercial and clinical experience in the U.S. healthcare market and its growing capabilities across precision medicine and drug development.

Precision oncology increasingly relies on integrating multiple types of patient data to account for differences in disease biology and treatment response. ImpriMed applies multimodal AI to patient-specific cancer cell characteristics, drug response profiles, and clinical information to enable more personalized treatment selection.

At the core of ImpriMed’s xCellSense^® platform is its ability to keep patient cancer cells viable ex vivo for extended periods, enabling evaluation of their biological characteristics and drug sensitivity. The platform combines these results with immunophenotypic, genomic, and clinical data to guide treatment decisions. ImpriMed is developing AI models trained on more than 3.5 million data points, combining real-world data with functional cell analysis to improve predictive accuracy.

ImpriMed is preparing to commercialize products for blood cancers and blood infection, targeting FDA clearance and CLIA certification by Q1 2027 for an initial U.S. launch. The company has also established business partnerships with major U.S. hospitals as it builds its human health presence in North America. In South Korea, ImpriMed has developed software for multiple myeloma prognosis and therapy-response predictions. The software has been designated an Innovative Medical Device by the Ministry of Food and Drug Safety (MFDS) and is progressing through the approval and commercialization process. ImpriMed also collaborates with leading tertiary hospitals, including Catholic University Seoul St. Mary’s Hospital, Seoul Asan Medical Center, and Gangneung Asan Hospital.

ImpriMed’s human healthcare expansion is supported by its commercial experience in veterinary precision oncology and its growing CRO business in drug development. In veterinary medicine, ImpriMed has performed more than 27,000 tests for canine and feline lymphoma to guide treatment decisions. A retrospective study showed a threefold increase in survival time and a fourfold improvement in treatment response, and the findings have been published in a peer-reviewed scientific journal. ImpriMed’s solutions are currently used by more than 600 veterinary hospitals across the United States, Canada, the United Kingdom, France, and South Korea.

ImpriMed was co-founded in Silicon Valley by CEO Sungwon Lim and CTO Jamin Koo, who studied together at KAIST and Stanford University. The company brings together expertise in biomedical research, AI modeling, clinical collaboration, and commercialization. Beyond North America, ImpriMed plans to expand into the European and Asian markets.

The $10 million bridge round follows ImpriMed’s $23 million Series A in 2023. The round was led by LB Investment, with participation from new investors NAVER D2SF, Samsung Securities, and Alois Ventures, as well as follow-on investments from existing investors BonAngels and Han River Partners.

NAVER D2SF continues to invest in healthcare startups targeting the North American market. Through NAVER D2SF’s founder network, portfolio companies such as Soundable Health, PranaQ, and NubiLab share local market knowledge and operating experience, fostering collaboration across R&D and go-to-market strategy.

About NAVER D2SF

NAVER D2SF is NAVER’s in-house corporate venture arm, supporting startups through investment and collaboration. Founded in 1999, NAVER has been Korea’s leading search engine for more than 20 years and operates across commerce, content, fintech, and cloud services. Guided by its technology vision of D2 (For Developers, By Developers), NAVER continues to develop new technologies and build global partnerships.

To learn more, visit https://d2sf.naver.com.

SOURCE NAVER D2SF

PLYMOUTH, Mich., Sept. 18, 2026 — Marel Power Solutions, Inc. announced today that it has been awarded $1.9 million through the Michigan Supplier Conversion Grant Program, administered by the Michigan Department of Labor and Economic Opportunity (LEO). Marel is one of eleven Michigan automotive suppliers selected to share $21 million in funding aimed at strengthening the state’s domestic automotive supply chain and preparing manufacturers for future vehicle technologies.

More information on the Michigan Supplier Conversion Grant Program and the 2026 award recipients is available through the Michigan Department of Labor and Economic Opportunity.

Marel Power develops power stacks, the building blocks inside every inverter and converter that moves energy between AC and DC, including electric vehicle traction inverters, battery disconnect units, onboard chargers, and charging infrastructure. It is a configurable platform rather than a component. The innovation is in how densely Marel Power packages power semiconductors and how aggressively it cools them. The platform is being deployed first in electric vehicles, and the same architecture extends to Defense and Data Center power systems.

“Power is the constraint on growth now,” said Amrit Vivekanand, CEO of Marel Power Solutions. “Customers need more power in less space, at lower weight, and lower cost. Marel can deliver the same power in roughly one-quarter of the space at 30% lower cost. This LEO funding gives us the equipment to build our power stacks at pilot scale here in Michigan. Because our platform is configurable and scalable, customers can select the configuration they need instead of paying for a new design from the ground up.”

The program is supported by the U.S. Department of Energy’s Domestic Automotive Manufacturing Conversion Grant program, which is intended to increase domestic manufacturing capacity for qualified vehicles and their components while helping established automotive suppliers adapt to changes in the industry.

The same demand for higher power density is accelerating across Data Center and AI infrastructure, where rapidly increasing compute requirements are driving more power through increasingly constrained physical footprints. Marel’s compact, high-density power electronics architecture is designed to help power conversion systems deliver significantly more power within the same (or smaller) space, supporting the next generation of AI and data center infrastructure.

“AI is changing the power-density requirements of the data center,” said Vivekanand. “The challenge is no longer simply delivering more power, it is delivering dramatically more power without requiring dramatically more space. That is exactly where Marel’s technology provides an advantage. By shrinking the power electronics footprint, we can help infrastructure providers use valuable space for compute instead of power conversion.”

For Marel Power, the award funds equipment for a pilot production line in Plymouth, beginning with electric vehicle applications.

About Marel Power Solutions

Marel Power Solutions is tackling the power challenge that will define the next decade of growth. Its configurable power stack platform shrinks the inverter at the heart of every high-power system, giving data centers more compute per rack, automakers lighter and lower-cost EV powertrains, and defense platforms smaller, lighter vehicles without sacrificing performance. Headquartered in Plymouth, Michigan, Marel lets customers order a configuration instead of funding a new design from scratch. Learn more at marel-power.com.

SOURCE Marel Power Solutions

• CEO Kwak Noh-Jung and key executives, alongside global VCs and startup leaders, attend the inaugural ‘SK hynix Ventures Day’ in Silicon Valley
• Company to expand investments across the entire AI ecosystem
• Discussing strategies to strengthen partnerships with global venture firms and investors in future technology fields such as AI data centers and optical-based systems

SEOUL, South Korea, Sept. 18, 2026 — SK hynix Inc. (or “the company”, www.skhynix.com) announced today the launch of its corporate venture capital (CVC) brand, “SK hynix Ventures,” aimed at expanding strategic partnerships within the global AI ecosystem and securing future innovative technologies.

To mark the occasion, SK hynix held the inaugural “SK hynix Ventures Day” in Silicon Valley, where executives shared investment strategies with global venture capitalists and startup representatives while discussing future technological cooperation to respond to shifts in the AI industry.

The event was attended by CEO Kwak Noh-Jung and key executive leadership, alongside representatives from global VC firms and executives from leading startups.

• Expanding Beyond Tech Sensing to Become a Strategic Partner in the AI Ecosystem

Since 2015, SK hynix has operated a CVC organization, pursuing both direct investments and indirect investments via fund commitments in promising early-stage startups within the semiconductor and emerging tech sectors. By investing in enterprises across key regions including the U.S., China, Israel, and Japan, the company has achieved returns exceeding twice its cumulative investment to date. Furthermore, it has accumulated a track record of discovering new supply chains and customers by pursuing technological collaborations—such as joint equipment development and Proof of Concept (PoC)—with portfolio companies.

While past CVC activities focused primarily on “Tech Sensing” to explore future technology trends and “Path Finding” to discover new business opportunities, the company now plans to expand its CVC scope. Driven by recent advancements in AI technology and industry expansion, the role will evolve from simply discovering promising companies to leading collaborative innovation across the entire ecosystem.

• Discussing Cooperation in AI Computing, Data Centers, and Optical Interconnect

Through SK hynix Ventures, the company plans to broaden its investment scope from traditional semiconductors and emerging tech to the broader AI ecosystem. SK hynix aims to discover technologies and companies with high growth potential in core AI industry sectors—including AI computing, data centers, system software, and optical interconnect—and continually expand its CVC investments.

Meanwhile, the event was attended by promising startups in the U.S. AI computing and data center technology sectors. These companies shared perspectives on future technological innovations, discussing the growing importance of computing, memory, and system software innovations driven by advanced AI models, alongside the performance and power efficiency of optical-based systems for AI data centers.

“Competitiveness in the AI era stems not just from rapidly securing innovative technologies, but from ecosystem capabilities where customers, partners, and startups create new value together,” said Kwak Noh-Jung, CEO of SK hynix. “Through SK hynix Ventures, we will support the growth of promising companies and grow into a global partner that jointly designs the future of AI infrastructure based on strategic investments and technological cooperation.”

About SK hynix Inc.
SK hynix Inc., headquartered in Korea, is the world’s top-tier semiconductor supplier offering Dynamic Random Access Memory chips (“DRAM”) and flash memory chips (“NAND flash”) for a wide range of distinguished customers globally. The Company’s common shares are traded on the Korea Exchange, its American Depositary Shares are traded on NASDAQ, and its Global Depository Shares are listed on the Luxembourg Stock Exchange. Further information about SK hynix is available at www.skhynix.com, news.skhynix.com.

SOURCE SK hynix Inc.

HCTI to serve as U.S. technology and capital-markets partner, bringing AI, cloud and data expertise as ARCB and Kanzun launch cross-border healthcare investment platform

PLEASANTON, Calif., Sept. 17, 2026 — Healthcare Triangle, Inc. (Nasdaq: HCTI) (“HCTI” or the “Company”), a U.S.-based healthcare technology company, today announced that it has signed on as the U.S. technology and capital-markets partner for a new fund built to move Malaysian healthcare companies to the world stage. The Kanzun-ARCB Growth Fund launched through a Memorandum of Understanding signed in Kuala Lumpur, Malaysia, pairing Dubai-based ARCB Investment LLC’s (“ARCB”) capital network with Kanzun Ventures Management Sdn. Bhd.’s (“Kanzun”) deal experience on the ground in Malaysia. HCTI’s role will be to get qualifying companies ready, technologically and financially, for a successful run at the U.S. capital markets.

ARCB brings roughly AED 300 million in assets under management and a network of family offices, institutional investors and strategic partners across the Middle East and Asia. The firm opened its Asia-Pacific office in Kuala Lumpur in April 2026, and the Kanzun-ARCB Growth Fund marks its first major platform launch in the region. Together with Kanzun and HCTI, the three parties are building a structured corridor connecting Malaysian healthcare companies to Middle Eastern capital and, from there, to U.S. capital markets.

How the Partnership Will Work

Kanzun will lead the deal sourcing, due diligence, valuation and portfolio development in Malaysia, identifying healthcare companies with real growth potential. ARCB anchors the fund’s capital formation, drawing on its investor network across the Middle East and Asia. HCTI steps in once a target companies are ready for thier next stage of growth. The Company applies its Nasdaq-listed experience and its expertise in artificial intelligence, cloud, data and digital infrastructure to help build the technology foundation and market readiness a U.S. expansion requires.

Management’s Comments

Dr Suresh Venkatachari, Founder and Head of M&A of Healthcare Triangle, Inc., said: “We are pleased to collaborate with ARCB and Kanzun Ventures in evaluating opportunities within the Malaysian AI and healthcare sector. We look forward to supporting qualifying companies in their AI technology transformation and evaluating appropriate strategic pathways to expand in U.S. markets.”

Dr Chaskar U., Chief Executive Officer of ARCB Group, said: “Since establishing our ASEAN presence in Kuala Lumpur this April, we have been deliberate about where and how ARCB deploys capital in this region. Malaysia’s healthcare sector is full of founders who have built genuinely strong businesses but have not yet had access to the institutional capital, governance and international positioning needed to compete globally. That is precisely the gap ARCB exists to close. With Kanzun’s execution capability on the ground and Healthcare Triangle’s technology and U.S. market experience, we are building more than a fund — we are building a corridor that connects Malaysian healthcare champions to Middle Eastern capital and, from there, to the U.S. capital markets. This is what our ASEAN strategy was always designed to deliver.”

Mr Loganathan S., Chief Executive Officer of Kanzun Ventures Management Sdn. Bhd., said: “Malaysia has healthcare entrepreneurs who have spent many years building strong businesses, but many of these companies remain relatively small from an international capital-market perspective. Working with ARCB gives us access to an international capital network, while our collaboration with Healthcare Triangle provides an important connection to healthcare technology and the U.S. market.”

About Healthcare Triangle, Inc.

Healthcare Triangle, Inc. (Nasdaq: HCTI), based in Pleasanton, California, reinforces healthcare progress through breakthrough technology and extensive industry knowledge and expertise. The Company supports healthcare organizations — including hospitals and health systems, payers, and pharma/life sciences organizations — in their effort to improve health outcomes through better utilization of the data and information technologies they rely on. Healthcare Triangle’s Cloud and Data Platform (CaDP), marketed as CloudEz™ and DataEz™, has achieved HITRUST Risk-based, 2-year (r2) Certified status, demonstrating to clients the highest standards for data protection and information security. Healthcare Triangle enables the adoption of new technologies, data enlightenment, business agility, and response to immediate business needs and competitive threats. The highly regulated healthcare and life sciences industries rely on Healthcare Triangle for expertise in digital transformation encompassing cloud, security and compliance, data lifecycle management, healthcare interoperability, and clinical and business performance optimization.

About ARCB Investment LLC

ARCB Investment LLC is a UAE fund house established in 2022 and a Mainland investment management licensed company (License No. 1041252), under the leadership of Chairman His Excellency Dr Mohammed Saeed Al Kindi, a former UAE Minister and diplomat, and Chief Executive Officer Dr Chaskar U. ARCB manages assets under management of approximately AED 300 million across ten sectors, including energy, water, healthcare, education, agriculture, industry, tourism, sports, technology and commercial real estate. ARCB is a participant of the United Nations Global Compact.

About Kanzun Ventures Management Sdn. Bhd.

Kanzun Ventures Management Sdn. Bhd. is a Malaysia-based venture capital management corporation registered with the Securities Commission Malaysia. Kanzun focuses on identifying, structuring and developing investment opportunities with the potential for significant growth and strategic value, including opportunities across healthcare and healthcare-related industries.

Forward-Looking Statements and Safe Harbor Notice

This press release contains forward-looking statements concerning the proposed collaboration among Healthcare Triangle, Inc., ARCB Investment LLC and Kanzun Ventures Management Sdn. Bhd., including statements regarding potential investments, acquisitions, capital raising, technology integration, strategic transactions and potential U.S. capital-market opportunities for Malaysian healthcare companies. References to targeted healthcare companies or segments in this announcement should not be interpreted as confirmation that any acquisition, investment, consolidation or U.S. listing has been completed. Any proposed transaction remains subject to due diligence, audit, valuation, negotiations, corporate and regulatory approvals, financing and the execution of definitive agreements. Nothing contained in this announcement constitutes an offer to sell or a solicitation of an offer to purchase securities or interests in any fund, company or investment vehicle. Any reference to Nasdaq or the U.S. capital markets represents a strategic objective or potential pathway only and does not constitute a representation or guarantee that any company will be listed on Nasdaq or complete any U.S. capital-market transaction.

All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate.” The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions, including market and other conditions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors outlined in the Company’s annual report on Form 10-K for the year ended December 31, 2025, on file with the Securities and Exchange Commission (the “SEC”) and in previous filings, subsequent filings and future periodic reports filed with the SEC. All the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

Investor Contact

Healthcare Triangle, Inc.
1-800-617-9550
[email protected]

SOURCE Healthcare Triangle, Inc.

Silicon Valley lender is building a private-bank-style mortgage platform for founders, self-employed entrepreneurs, business owners and high-net-worth borrowers who don’t fit traditional agency underwriting

DANVILLE, Calif., Sept. 17, 2026 — As Non-QM mortgage lending continues to expand, RateSecure sees the market separating into two distinct segments: traditional alternative-credit lending and a private-bank-style approach designed for financially strong borrowers with complex income and wealth profiles.

“There are really two Non-QM markets emerging — traditional alternative-credit lending and private-bank-style lending for wealthy borrowers,” said Gurp Bhandal, Founder and CPO of RateSecure. “We built RateSecure around the second.”

For RateSecure, this is often a documentation gap, not a credit gap.

“Traditional mortgage underwriting works well for borrowers with predictable W-2 income, but entrepreneurship creates a different financial profile,” said Sam Bhandal, President and CEO of RateSecure. “A successful business owner shouldn’t become a difficult mortgage borrower simply because their income doesn’t fit neatly into a conventional calculation.”

For many self-employed borrowers, legitimate business deductions, reinvestment and multiple income sources can complicate qualification without necessarily indicating weaker financial strength.

Private-Bank Thinking at Silicon Valley Speed

Understanding a complex borrower is only part of the equation. In Silicon Valley’s ultra-competitive housing market, execution matters just as much as loan structure.

RateSecure is built to close complex loans in less than 10 days, giving founders, entrepreneurs and business owners the ability to compete on speed alongside borrowers with traditional W-2 income.

Complex wealth shouldn’t put a buyer at a competitive disadvantage.

“When a family finds the right home, the complexity of how they’ve built their wealth shouldn’t be the reason they lose it,” Gurp Bhandal said. “Our job is to understand the borrower, structure the financing correctly and execute at the speed the market demands.”

A Different Evolution of Non-QM

RateSecure believes the growth of self-employment, entrepreneurship and complex personal wealth is changing the role Non-QM plays in the mortgage industry.

Historically, Non-QM has often been viewed as an alternative for borrowers unable to qualify for conventional financing. RateSecure believes that definition increasingly misses an important part of the market.

“Non-QM isn’t simply about borrowers who can’t qualify conventionally,” Gurp Bhandal said. “There’s a growing segment of financially strong borrowers who simply need a more sophisticated way to document income and wealth.”

For RateSecure, those borrowers aren’t exceptions to its lending model. They are the reason the model exists.

“We’re building a mortgage company around founders, entrepreneurs, business owners and high-net-worth borrowers,” Sam Bhandal said. “The goal is to bring the level of understanding and individualized structuring associated with private banking into a modern mortgage platform.”

About RateSecure Financial

RateSecure Financial, Inc. is a California mortgage lender focused on founders, self-employed entrepreneurs, business owners, real estate investors and high-net-worth borrowers with complex income and wealth.

Complex Wealth. Strategic Lending. Exceptional Execution.

RateSecure Financial, Inc.
NMLS #2815879
CA DFPI California Financing Law License #60DBO-217750
675 Hartz Avenue, Suite 103
Danville, CA 94526
(866) 351-RATE
[email protected]

SOURCE RateSecure